20 results about "Oil adjuvant" patented technology

The invention provides a water-in-oil adjuvant for animal vaccines and a preparation method and application thereof, and relates to the technical field of biology, the water-in-oil adjuvant comprises 73%-75% of oil for injection, 20%-23% of an emulsifier and 2%-7% of a stabilizer; the emulsifying agent is prepared from 4.5 percent to 5 percent of polyoxyethylene fatty alcohol ether, 3.0 percent to 3.5 percent of glycerol monoisostearate, 7.0 percent to 8.0 percent of span 80, 4.5 percent to 5 percent of Tween 80 and 1 percent to 1.5 percent of vitamin E; the vaccine prepared from the water-in-oil adjuvant has the advantages that the viscosity is reduced, and the injection is easy. The technical problems that in the prior art, a vaccine prepared from an oil-in-water adjuvant is large in viscosity, so that resistance is large during injection, the occurrence rate of side reactions is high, an injection part swells, and granuloma is formed are solved.

The invention provides a two-phase oil adjuvant as well as a preparation method and application thereof, and relates to the technical field of oil adjuvants, the two-phase oil adjuvant comprises the following components: mineral oil, castor oil polyoxyethylene ether, TWeen 80, Span80, mannitol dicondensation, tocopherol, triethanolamine and sodium hydroxide. The vaccine emulsion can prevent antigen degradation in the long-term preservation process of vaccines, can reduce the interfacial tension between oil and water, improves the integrity and strength of an interfacial film, reduces the diameter of liquid drops, and is uniformly dispersed in a system, so that the stability of the emulsion is effectively improved; in a word, the two-phase oil adjuvant disclosed by the invention achieves the technical effects of effectively improving the antigen protection rate of vaccines and improving the stability of the emulsion.

The present invention relates to vaccination against animal pathogens using alpha virus-replicon RNA particles and oil adjuvants. To vaccines and kits comprising said replicon particles and said oil adjuvant. The invention also relates to methods and uses for preparing and using the vaccine and the components of the kit.

The invention relates to the technical field of virus gene engineering, in particular to a construction method of a porcine respiratory syndrome virus, which comprises the following steps: taking a PRRSV HEB1 strain genome (GenBankEF112447.1) as a template, modifying the template, cloning the modified genome to a pBAC11 vector, and rescuing a recombinant virus rPRRSV-HA-CMV-mC through in vitro transcription and Marc-145 cell transfection. The recombinant PRRSV strain shows remarkable replication delay and titer reduction, and an attenuated phenotype is formed. The recombinant virus and an ISA206 oil adjuvant are further emulsified to prepare the vaccine, the vaccine shows efficient immunogenicity in piglet immunization, clinical symptoms, viremia and lung pathological injury after PRRSV infection can be remarkably reduced, and the vaccine has the potential of being developed into a safe and effective vaccine.

The invention discloses a recombinant tetanus toxin protein rTT as well as a preparation method and application thereof, the recombinant protein sequentially contains a His tag, a modified exogenous polypeptide and two tetanus toxin fragments connected in series through flexible polypeptides from the N end to the C end, the two tetanus toxin fragments connected in series form two intramolecular disulfide bonds in a molecule through double mutation, and the tetanus toxin fragments are connected in series through flexible polypeptides. Coding nucleotide of the recombinant protein is expressed by escherichia coli BL21 (DE3), induced at low temperature and purified, and target protein with the purity larger than or equal to 95% can be obtained. A subunit vaccine prepared from the protein and a two-way oil adjuvant ISA201 enables mice to achieve 100% protection under 100 LD50 challenge dose, the protection effect is better than that of truncated tetanus toxin heavy chain fragment TTc protein, and the recombinant protein can be used for tetanus prevention vaccines and serological diagnostic reagents.

The application relates to the technical field of virus genetic engineering, and particularly relates to a construction method of a porcine respiratory syndrome virus. The construction method is as follows: taking a PRRSV HEB1 strain genome (GenBank EF112447.1) as a template and modifying the same, then cloning the modified genome into a pBAC11 carrier, carrying out in-vitro transcription and transfecting Marc-145 cells, and rescuing a recombinant virus rPRRSV-HA-CMV-mC. The recombinant PRRSV strain shows significant replication delay and titer reduction, forming an attenuated phenotype. Further, the recombinant virus is emulsified with an ISA206 oil adjuvant to prepare a vaccine, which shows high immunogenicity in piglet immunization, can significantly reduce clinical symptoms, viremia and lung pathological damage after PRRSV infection, and has the potential to be developed into a safe and effective vaccine.

The invention belongs to the technical field of biology, mainly relates to a preparation method of a composite adjuvant, and particularly relates to a water-soluble immune composite adjuvant, a vaccine and a preparation method of the vaccine. According to the compound adjuvant, every 300 mL of the compound adjuvant is prepared from 30 mL to 50 mL of carbomer stock solution, 30 mL to 37.5 mL of polyinosinic stock solution, 800 mg to 900 mg of triterpenoid saponin, 1.2 g of chitosan oligosaccharide and 20 mL of chitosan solution. Wherein the concentration of the carbomer stock solution is 30 mg / mL, the concentration of the polyinosinic-polycytidylic acid stock solution is 50 mg / mL, and the concentration of the chitosan solution is 600 mg / mL. The water-soluble immune composite adjuvant disclosed by the invention does not contain mineral oil components, granuloma of an injection part caused by viscous oil adjuvant vaccines is avoided, the water-soluble immune composite adjuvant is conveniently mixed with antigens in use, the economic benefits and the use convenience of farmers are effectively improved, and the water-soluble immune composite adjuvant is easy to industrially produce. And meanwhile, the gleditsia sinensis saponin enzymatic hydrolysate and the chitosan oligosaccharide enzymatic hydrolysate contained in the adjuvant have a synergistic effect, so that a relatively strong immune effect is achieved, humoral immune response and cellular immune response can be stimulated, and the immune persistence can be enhanced.

The invention provides an application of an aeromonas hydrophila Ah-221212 strain in preparation of a vaccine for preventing septicemia of aquatic animals caused by aeromonas hydrophila. The inactivated vaccine prepared from the specific aeromonas hydrophila Ah-221212 strain has the advantages of simple preparation steps and low cost, can have multiple functions of targeted delivery, self-adjuvant effect, slow release and the like, does not need to additionally add traditional adjuvants such as an aluminum adjuvant and an oil adjuvant, and is a novel aeromonas hydrophila aeromonas hydrophila vaccine with excellent performance.

The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and an oil adjuvant. The invention also relates to vaccines and kits comprising the replicon particles and the oil adjuvant. The invention also relates to methods and uses of the components of the vaccine and the kits.

The present application relates to the field of biological medicine, and particularly relates to a recombinant herpes zoster vaccine composition and a preparation method thereof.The recombinant herpes zoster vaccine composition comprises gE protein and an adjuvant, the adjuvant is squalene oil-in-water, and the squalene oil-in-water adjuvant comprises the following concentration components: squalene: 4-5 wt%; Tween 80: 0.2-0.8 wt%; Span 85: 0.2-0.8 wt%. The vaccine composition can specifically enhance the cellular immune response to varicella-zoster virus, can significantly improve the expression of cytokines such as INF-gamma and IL-2 of CD4+ T cells in mice, and can improve the level of humoral and cellular immune response, shows high immunocompetence for preventing varicella-zoster virus infection in clinic, and the components in the vaccine composition are cheap and easy to obtain, effectively improve the yield of the vaccine, and reduce the cost of the vaccine.

The invention discloses an oil-in-water adjuvant for vaccines and a preparation method of the oil-in-water adjuvant. The oil-in-water adjuvant for the vaccine is prepared from isopropyl myristate, alpha-tocopherol, trehalose, an oil-phase mother solution and a PBS (Phosphate Buffer Solution). The invention also provides a preparation method of the composition. Compared with the prior art, the oil-in-water adjuvant for the vaccine, which has long-term physical stability, controllable dropping diameter, low foaming and controlled oxidation under the condition of 2-8 DEG C, is constructed on the premise of reducing the intervention of a small molecular surfactant as much as possible, and meanwhile, the compatibility and operability with an antigen system are ensured.

The invention provides application of a polyinosinic-polycytidylic acid combined water-in-oil adjuvant in preparation of animal vaccines or animal virus antiserum, and belongs to the technical field of animal virology. The invention provides application of a polyinosinic-polycytidylic acid combined water-in-oil adjuvant in preparation of animal vaccines or animal virus antiserum. According to the invention, the polyinosinic acid is used as the immunopotentiator and is matched with the water-in-oil adjuvant, so that the immune effect can be remarkably enhanced, and compared with a group without the polyinosinic acid, the titer of a neutralizing antibody of the prepared serum is increased by 3-4 times. The invention also provides a preparation method of the virus positive serum. According to the invention, the inactivated antigen prepared by the polyinosinic-polycytidylic acid combined with the water-in-oil adjuvant and the active virus antigen are used for alternative immunization, so that the titer of a neutralizing antibody can be improved by more than 10 times; the prepared virus positive serum can fully meet the requirements of product quality control on an inspection reagent in the aspects of titer and specificity.

The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and oil adjuvants. To a vaccine, and a kit of parts comprising the replicon particles and the oil adjuvant. Also to methods and uses of making and using the vaccine and the components of the kit.

The invention provides an adjuvant for an oil-in-water animal vaccine. The adjuvant contains 8.8%-19.6% of mineral oil, 3.7%-6.6% of span 80, 6.1%-11.0% of Tween 80, 3.9%-7.0% of glycerol, 2.9%-5.3% of polyglycerol ester and the balance of water for injection, wherein the total percentage of the adjuvant is 100%. The oil-in-water adjuvant disclosed by the invention is simple in formula and simple in preparation method; the animal vaccine prepared by utilizing the adjuvant is good in physical stability, can be stored for more than 12 months at 4 DEG C, can be stored for 12 months at 25 DEG C and can be stored for 2 months at 37 DEG C, and the storage stability is obviously superior to that of similar products at home and abroad; the animal vaccine prepared from the adjuvant is low in viscosity and easy to inject, no visible residue exists in animal experiments, death or obvious adverse reaction caused by vaccine injection is avoided, and guarantee is provided for vaccine injection safety and effectiveness and economic animal food safety.

The application relates to the technical field of vaccine adjuvants, and discloses an oil-in-water adjuvant, a preparation method and application thereof. The adjuvant comprises an oil phase, a composite surfactant, an interface polarity adjusting component and an aqueous phase; the interface polarity adjusting component is 1,3-butanediol; the composite surfactant is composed of polyoxyethylene hydrogenated castor oil with a polyoxyethylene unit number of 35 to 45 and sorbitan monooleate; the hydrogen bond anchoring network formed by 1,3-butanediol and the polyoxyethylene segment is utilized to increase the interface desorption energy barrier and improve the interface film expansion modulus, to inhibit the coalescence of the oil phase droplets under the condition of ultrahigh dilution and low shear, to spontaneously maintain the nanoscale particle size distribution, the static interface structure constructed by the application effectively offsets the physical failure caused by dilution, reduces the system kinetic viscosity to reduce injection stress, and cooperatively improves the antigen loading specific surface area and the immune induction effect.

The utility model discloses an oil adjuvant inactivated vaccine mixing equipment relates to inactivated vaccine mixing technical field, including heating jar, the inside cooperation and installation of heating jar have mixing jar, the bottom of mixing jar is conical structure, the bottom of mixing jar is equipped with the liquid outlet, the bottom fixed mounting of heating jar has the transfusion pipe, the bottom setting of heating jar installs and is equipped with filling assembly, the top setting of heating jar installs and is equipped with stirring assembly. The utility model design scheme is through the bottom of mixing jar conical structure's design, the bottom of mixing jar is equipped with the liquid outlet, under the action of filling assembly, the vaccine in mixing jar is discharged outward through the liquid outlet and fills, the vaccine in mixing jar will be under the direction of the conical surface, all from the discharge of mixing jar, avoid the vaccine residual in mixing jar, thereby avoid the waste condition to take place.

The invention provides a duck plague virus QL2312, and further provides application of the duck plague virus QL2312 in preparation of a duck plague virus infected animal model and application of the duck plague virus QL2312 in preparation of vaccines for preventing duck plague virus infected diseases. The duck plague virus QL2312 strain attacks 2-12 month-old susceptible ducks, and the death rate of the infected ducks reaches 100%. The QL2312 strain is inactivated by formaldehyde and then emulsified with an oil adjuvant to prepare an inactivated vaccine for immunizing test ducks, and the duck plague virulent AV1221 strain is used for challenging to verify the protection capability of the inactivated vaccine. Experimental results show that the survival rate of 2-12-month-old ducks immunized by the inactivated vaccine is kept consistent with that of duck plague live vaccines, and the survival rate of 1-21-day-old ducks immunized by the inactivated vaccine is remarkably superior to that of commercially available duck plague live vaccines. Therefore, the separated and purified QL2312 strain can be used for preparing inactivated vaccines and can effectively prevent death caused by duck plague infection of ducks of different day ages.

The application provides a water-in-oil adjuvant for poultry animal vaccines and a preparation method and application thereof, and belongs to the technical field of biological product animal vaccines. The raw materials of the water-in-oil adjuvant provided by the application include, in percentage by mass, 85wt%-90wt% of injection oil, 5wt%-10wt% of refined Span-80 and 1wt%-5wt% of refined Tween-80, and can further include 0.1wt%-1wt% of an immune stimulating complex. The vaccine prepared by using the water-in-oil adjuvant provided by the application is stable in quality, high in safety, and can induce the body to produce an immune response with a longer duration and higher efficiency, and therefore can be used as a safe and effective adjuvant for poultry animal vaccines and the like.

The invention relates to the technical field of vaccine immunization, in particular to a compound oil adjuvant as well as a preparation method and application thereof. The compound oil adjuvant is prepared from the following components in percentage by mass: 1 to 6 percent of squalene, 0.5 to 3.0 percent of a surfactant, 0.02 to 0.5 percent of a nano slow-release agonist, 0.1 to 1.2 percent of a biodegradable polymer, 3 to 7 percent of an isotonic agent and the balance of a buffer solution, wherein the nano sustained-release agonist jointly encapsulates a Mincle agonist trehalose 6, 6 '-behenate and a TLR4 agonist CRX-675 through a lipid carrier, a fucoidin and sodium hyaluronate stabilizing system is adopted, and the nano sustained-release agonist is integrated into the squalene emulsion after being subjected to surface modification by a biodegradable polymer. Targeted delivery and slow release of double agonists are realized, and an immune signal channel is synergistically activated, so that the immune response of vaccine body fluid and cells is remarkably improved, and excellent physical stability and safety are achieved. The invention further discloses a preparation method of the adjuvant and application of the adjuvant in preparation of inactivated vaccines.

The present invention relates to an oil adjuvant composition comprising at least one oil; at least one non-ionic lipophilic surfactant, wherein the at least one non-ionic lipophilic surfactant is dehydrated sorbitol ester or dehydrated mannitol ester; and at least one nonionic hydrophilic surfactant, the at least one nonionic hydrophilic surfactant being an ethoxylated fatty alcohol. The invention also relates to an oil-in-water adjuvant emulsion and an oil-in-water vaccine emulsion obtained from the oil adjuvant composition of the invention, and to the use of such an oil-in-water vaccine emulsion for the treatment of porcine circovirus type 2 disease and / or porcine endemic pneumonia.